Full Text Journal Articles by
Author Pauline Wimberger

Advertisement

Find full text journal articles






Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group.

Fabian Trillsch, Sven Mahner, Bastian Czogalla, Miriam Rottmann, Radoslav Chekerov, Elena Ioana Braicu, Gülten Oskay-Öczelik, Pauline Wimberger, Rolf Richter, Jalid Sehouli,

<h4>Objective</h4>Patients with platinum-resistant ovarian cancer (PROC) have a high need for reliable prognostic markers. Since significance of primary platinum resistance (PPR) versus secondary platinum resistance (SPR) was identified for patients receiving anti-angiogenic therapy, it has not been confirmed for chemotherapy only.<h4>Methods</h4>PROC patients from 3 prospective trials of the NOGGO study ... Read more >>

J Gynecol Oncol (Journal of gynecologic oncology)
[2021, 32(3):e37]

Cited: 0 times

View full text PDF listing >>



SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.

,

<h4>Background</h4>Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling.<h4>Methods</h4>The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an ... Read more >>

Br J Surg (The British journal of surgery)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.

Peter A Fasching, Siddhartha Yadav, Chunling Hu, Marius Wunderle, Lothar Häberle, Steven N Hart, Matthias Rübner, Eric C Polley, Kun Y Lee, Rohan D Gnanaolivu, Peyman Hadji, Hanna Hübner, Hans Tesch, Johannes Ettl, Friedrich Overkamp, Michael P Lux, Arif B Ekici, Bernhard Volz, Sabrina Uhrig, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Erik Belleville, Michael Untch, Hans-Christian Kolberg, Matthias W Beckmann, André Reis, Arndt Hartmann, Wolfgang Janni, Pauline Wimberger, Florin-Andrei Taran, Tanja N Fehm, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss, Andreas D Hartkopf, Fergus J Couch,

<h4>Purpose</h4>Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, :JCO2001200]

Cited: 0 times

View full text PDF listing >>



Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.

Daniel Martin Klotz, Theresa Link, Pauline Wimberger, Jan Dominik Kuhlmann,

The pleiotropic protein hepatocyte growth factor (HGF) is the only known ligand of the tyrosine kinase mesenchymal-epithelial transition (cMET) receptor. The HGF/cMET pathway mediates invasion and migration of ovarian cancer cells, and upregulation of HGF/cMET pathway components has been associated with poor prognosis. This study investigated the clinical relevance of ... Read more >>

Mol Oncol (Molecular oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.

Daniel Martin Klotz, Theresa Link, Maren Goeckenjan, Pauline Wimberger, Jan Dominik Kuhlmann,

The tyrosine kinase mesenchymal-epithelial transition (cMET) is typically overexpressed in up to 75% of patients with ovarian cancer, and cMET overexpression has been associated with poor prognosis. The proteolytic release of the soluble cMET (sMET) ectodomain by metalloproteases, a process called ectodomain shedding, reflects the malignant potential of tumour cells. ... Read more >>

Mol Oncol (Molecular oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study.

Katharina Prieske, Linn Woelber, Mustafa Zelal Muallem, Christine Eulenburg, Julia Kathrin Jueckstock, Felix Hilpert, Nikolaus de Gregorio, Severine Iborra, Atanas Ignatov, Peter Hillemanns, Sophie Fuerst, Hans-Georg Strauss, Klaus Baumann, Matthias Beckmann, Alexander Mustea, Werner Meier, Philipp Harter, Pauline Wimberger, Jalid Sehouli, Sven Mahner,

<h4>Background</h4>Despite an increasing incidence with simultaneous decreasing age of onset, vulvar squamous cell carcinoma (VSCC) is still a disease that mainly effects the elderly population. Data on the association of age with prognosis and treatment patterns in VSCC are sparse.<h4>Methods</h4>This is an analysis of the AGO-CaRE-1 cohort. Patients with VSCC ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



CRBP-TS - evaluation of a home-based training and health care program for colorectal, breast, and prostate cancer using telemonitoring and self-management: study protocol for a randomized controlled trial.

Roberto Falz, René Thieme, Uwe Tegtbur, Christian Bischoff, Christian Leps, Peter Hillemanns, Kay Kohlhaw, Jürgen Klempnauer, Florian Lordick, Jens-Uwe Stolzenburg, Bahriye Aktas, Jürgen Weitz, Ulrich Bork, Pauline Wimberger, Christian Thomas, Ronald Biemann, Boris Jansen-Winkeln, Antina Schulze, Ines Gockel, Martin Busse,

<h4>Background</h4>Physical training is recommended in various national and international guidelines for patients with cancer. Observational studies have shown that physical activity leads to reduced recurrence and mortality rates by 20-40% in colorectal, breast, and prostate cancer. Despite existing evidence, a systematic care structure is still lacking. The primary aim of ... Read more >>

BMC Sports Sci Med Rehabil (BMC sports science, medicine & rehabilitation)
[2021, 13(1):15]

Cited: 0 times

View full text PDF listing >>



ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Nicole Concin, Carien L Creutzberg, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan A Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio González-Martín, Sigurd F Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A Nout, Dearbhaile E O'Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina E Sturdza, Alexandra Taylor, Anneke M Westermann, Pauline Wimberger, Nicoletta Colombo, François Planchamp, Xavier Matias-Guiu,

A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and ... Read more >>

Virchows Arch (Virchows Archiv : an international journal of pathology)
[2021, 478(2):153-190]

Cited: 0 times

View full text PDF listing >>



ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio Gonzalez Martin, Sigurd Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A Nout, Dearbhaile O'Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina Sturdza, Alexandra Taylor, Anneke Westermann, Pauline Wimberger, Nicoletta Colombo, François Planchamp, Carien L Creutzberg,

A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and ... Read more >>

Radiother Oncol (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology)
[2021, 154:327-353]

Cited: 0 times

View full text PDF listing >>



Placenta accreta spectrum disorders-experience of management in a German tertiary perinatal centre.

Anja Bluth, Axel Schindelhauer, Katharina Nitzsche, Pauline Wimberger, Cahit Birdir,

<h4>Purpose</h4>Placenta accreta spectrum (PAS) disorders can cause major intrapartum haemorrhage. The optimal management approach is not yet defined. We analysed available cases from a tertiary perinatal centre to compare the outcome of different individual management strategies.<h4>Methods</h4>A monocentric retrospective analysis was performed in patients with clinically confirmed diagnosis of PAS between ... Read more >>

Arch Gynecol Obstet (Archives of gynecology and obstetrics)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.

Elena Laakmann, Julius Emons, Florin-Andrei Taran, Wolfgang Janni, Sabrina Uhrig, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Carla Schulmeyer, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Bernhard Volz, Peter A Fasching, Tanja N Fehm, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss, Michael P Lux, Andreas D Hartkopf,

[This corrects the article DOI: 10.1055/a-1286-2917.]. ... Read more >>

Geburtshilfe Frauenheilkd (Geburtshilfe und Frauenheilkunde)
[2020, 80(11):e289]

Cited: 0 times

View full text PDF listing >>



Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".

Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W Beckmann, Erik Belleville, Peter A Fasching, Tanja N Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M Kurbacher, Evelyn Klein, Michael P Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y Brucker,

Breast (Breast (Edinburgh, Scotland))
[2021, 55:138-139]

Cited: 0 times

View full text PDF listing >>



ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio Gonzalez Martin, Sigurd Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A Nout, Dearbhaile O'Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina Sturdza, Alexandra Taylor, Anneke Westermann, Pauline Wimberger, Nicoletta Colombo, François Planchamp, Carien L Creutzberg,

A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2021, 31(1):12-39]

Cited: 11 times

View full text PDF listing >>



Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Javier Cortes, David W Cescon, Hope S Rugo, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H Barrios, Esther Holgado, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gokmen, Sherene Loi, Zifang Guo, Jing Zhao, Gursel Aktan, Vassiliki Karantza, Peter Schmid, ,

<h4>Background</h4>Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer.<h4>Methods</h4>In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites ... Read more >>

Lancet (Lancet (London, England))
[2020, 396(10265):1817-1828]

Cited: 17 times

View full text PDF listing >>



Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?

Linn Woelber, Mareike Bommert, Katharina Prieske, Inger Fischer, Christine Zu Eulenburg, Eik Vettorazzi, Philipp Harter, Julia Jueckstock, Felix Hilpert, Niko de Gregorio, Severine Iborra, Jalid Sehouli, Atanas Ignatov, Peter Hillemanns, Sophie Fuerst, Hans-Georg Strauss, Klaus Baumann, Matthias Beckmann, Alexander Mustea, Werner Meier, Pauline Wimberger, Lars Hanker, Ulrich Canzler, Tanja Fehm, Alexander Luyten, Martin Hellriegel, Jens Kosse, Christoph Heiss, Peer Hantschmann, Peter Mallmann, Berno Tanner, Jacobus Pfisterer, Sven Mahner, Barbara Schmalfeldt, Anna Jaeger,

Since the publication of the updated German guideline in 2015, the recommendations for performing pelvic lymphadenectomy (LAE) in patients with vulvar cancer (VSCC) have changed considerably. The guideline recommends surgical lymph node staging in all patients with a higher risk of pelvic lymph node involvement. However, the current data do ... Read more >>

Geburtshilfe Frauenheilkd (Geburtshilfe und Frauenheilkunde)
[2020, 80(12):1221-1228]

Cited: 0 times

View full text PDF listing >>



Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.

Maud Kamal, Sonia Lameiras, Marc Deloger, Adeline Morel, Sophie Vacher, Charlotte Lecerf, Célia Dupain, Emmanuelle Jeannot, Elodie Girard, Sylvain Baulande, Coraline Dubot, Gemma Kenter, Ekaterina S Jordanova, Els M J J Berns, Guillaume Bataillon, Marina Popovic, Roman Rouzier, Wulfran Cacheux, Christophe Le Tourneau, Alain Nicolas, Nicolas Servant, Suzy M Scholl, Ivan Bièche, ,

<h4>Background</h4>Cervical cancer (CC) remains a leading cause of gynaecological cancer-related mortality with infection by human papilloma virus (HPV) being the most important risk factor. We analysed the association between different viral integration signatures, clinical parameters and outcome in pre-treated CCs.<h4>Methods</h4>Different integration signatures were identified using HPV double capture followed by ... Read more >>

Br J Cancer (British journal of cancer)
[2021, 124(4):777-785]

Cited: 1 time

View full text PDF listing >>



Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.

Elena Laakmann, Julius Emons, Florin-Andrei Taran, Wolfgang Janni, Sabrina Uhrig, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Carla Schulmeyer, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Bernhard Volz, Peter A Fasching, Tanja N Fehm, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss, Andreas D Hartkopf,

<b>Purpose</b> Pertuzumab and T-DM1 are two efficient anti-HER2 treatments for patients with HER2-positive advanced breast cancer. While pertuzumab is usually given in first-line treatment and T-DM1 in second-line treatment, standard therapy options seem to be exhausted up to now after the treatment of patients with these two therapy options. Therefore, ... Read more >>

Geburtshilfe Frauenheilkd (Geburtshilfe und Frauenheilkunde)
[2020, 80(11):1134-1142]

Cited: 0 times

View full text PDF listing >>



Implementing clinical practice guidelines: time to assess it.

Cristiana Sessa, Nicoletta Colombo, Carien L Creutzberg, Nicole Concin, Pauline Wimberger, Giuseppe Curigliano, Klizia Marinoni, Jean-Yves Douillard, George Pentheroudakis, Valter Torri, Stefan Rauh,

ESMO Open (ESMO open)
[2020, 5(6):e001130]

Cited: 0 times

View full text PDF listing >>



Serotonin Receptor 2A Activation Promotes Evolutionarily Relevant Basal Progenitor Proliferation in the Developing Neocortex.

Lei Xing, Nereo Kalebic, Takashi Namba, Samir Vaid, Pauline Wimberger, Wieland B Huttner,

Evolutionary expansion of the mammalian neocortex (Ncx) has been linked to increased abundance and proliferative capacity of basal progenitors (BPs) in the subventricular zone during development. BP proliferation is governed by both intrinsic and extrinsic signals, several of which have been identified. However, a role of neurotransmitters, a canonical class ... Read more >>

Neuron (Neuron)
[2020, 108(6):1113-1129.e6]

Cited: 0 times

View full text PDF listing >>



Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.

Laura L Michel, Andreas D Hartkopf, Peter A Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Bernhard Volz, Hanna Huebner, Pauline Wimberger, Carsten Hielscher, Christoph Mundhenke, Christian Kurbacher, Rachel Wuerstlein, Michael Untch, Friedrich Overkamp, Jens Huober, Wolfgang Janni, Florin-Andrei Taran, Michael P Lux, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss, Tanja N Fehm,

The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality ... Read more >>

Cancers (Basel) (Cancers)
[2020, 12(10):]

Cited: 0 times

View full text PDF listing >>



The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.

Catharina Wichmann, Daniel Martin Klotz, Hans-Joachim Zeiler, Ralf Axel Hilger, Konrad Grützmann, Alexander Krüger, Daniela Aust, Pauline Wimberger, Jan Dominik Kuhlmann,

<h4>Objectives</h4>Extending the therapeutic spectrum of PARP-inhibitors (PARPi) beyond BRCA1-deficiency and/or overcoming PARPi-resistance is of high clinical interest. This is particularly true for the identification of innovative therapeutic strategies for ovarian cancer, given the recent advances in the use of PARPi in clinical practice. In this regard, the combination of PARPi ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2020, 159(3):850-859]

Cited: 0 times

View full text PDF listing >>



Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?

Daniel Martin Klotz, Pauline Wimberger,

<h4>Purpose</h4>Ovarian cancer is the most lethal gynaecological malignancy. Despite the introduction of bevacizumab, standard chemotherapy has remained largely unchanged and the vast majority of patients will relapse within the first two years of diagnosis. However, results from recent clinical trials demonstrating clinical benefits of PARP inhibitor treatment are rapidly changing ... Read more >>

Arch Gynecol Obstet (Archives of gynecology and obstetrics)
[2020, 302(5):1087-1102]

Cited: 0 times

View full text PDF listing >>



Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.

Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W Beckmann, Erik Belleville, Peter A Fasching, Tanja N Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M Kurbacher, Evelyn Klein, Michael P Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y Brucker,

<h4>Purpose</h4>Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor-positive, HER2-negative (HR + HER2-) breast cancer (BC). However, real-world data on the implementation of therapy usage, efficacy, and toxicity have not yet been reported.<h4>Methods</h4>The PRAEGNANT registry was used to identify advanced HR + HER2- BC patients (n = 1136). ... Read more >>

Breast (Breast (Edinburgh, Scotland))
[2020, 54:88-95]

Cited: 0 times

View full text PDF listing >>



Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.

Andy Göbel, Valentina M Zinna, Stefania Dell'Endice, Nikolai Jaschke, Jan Dominik Kuhlmann, Pauline Wimberger, Tilman D Rachner,

<h4>Background</h4>Ovarian cancer remains the most fatal gynecological malignancy. Current therapeutic options are limited due to late diagnosis in the majority of the cases, metastatic spread to the peritoneal cavity and the onset of chemo-resistance. Thus, novel therapeutic approaches are required. Statins and amino-bisphosphonates are inhibitors of the mevalonate pathway, which ... Read more >>

BMC Cancer (BMC cancer)
[2020, 20(1):703]

Cited: 0 times

View full text PDF listing >>



Continuous Body Temperature Monitoring to Improve the Diagnosis of Female Infertility.

Maren Goeckenjan, Esther Schiwek, Pauline Wimberger,

<b>Introduction</b> Ovulatory dysfunction is a major cause of female infertility. We evaluated the use of continuous body temperature monitoring with a vaginal biosensor to improve standard diagnostic procedures for determining ovulatory dysfunction. <b>Material and Methods</b> This prospective interventional study was performed in a reproductive medicine department of a university hospital. ... Read more >>

Geburtshilfe Frauenheilkd (Geburtshilfe und Frauenheilkunde)
[2020, 80(7):702-712]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
2.3316 s